KMDA
Kamada LtdPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KMDA
this stock
Kamada Ltd
|
$432.71M | +9.5% | — | — | 0.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.99B | +7.6% | — | — | 0.3% |
|
GALDY
Galderma Group AG/ADR
|
$52.48B | +8.0% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.25B | -2.9% | — | — | 0.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KMDA | +4.5% | +1.5% | -2.8% | +2.2% | +9.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +3.0% | +2.7% | -10.8% | +2.5% | +0.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.